Lilly, BMS, Incyte strike deals to keep biopharma's AI integration rolling - BioSpace

Big companies don't buy AI tools and hope for the best. They plug AI into a system their team already uses every day.

That's the quiet lesson buried in this week's Lilly, BMS, and Incyte deals. These aren't billion-dollar companies ripping out their existing workflows. They're integrating AI directly into databases their researchers already live in.

Sound familiar? You bought that AI tool. Your team didn't use it. Not because they're resistant to change — because it lived outside their daily routine. A tool nobody opens is a tool nobody benefits from.

The companies getting real ROI from AI aren't adopting new platforms. They're connecting AI to existing ones.

Here's your one actionable takeaway: Before you evaluate any AI solution, list the three tools your team uses every single day. Then ask vendors only one question — does your AI work inside those tools, or does it replace them? That answer tells you everything about whether your team will actually use it.

That single filter can save you months of wasted spend and another "we bought it but nobody uses it" story.

What's one tool your team uses daily that you wish AI could just quietly improve — without disrupting everything around it?

#AIStrategy #SmallBusiness #BusinessGrowth #AIImplementation

Original Source

Through the agreement, the pharma will integrate its own AI engine Lilly TuneLab into CDD Vault, a database hosted and run by Collaborative Drug ...